Replies to post #76996 on Biotech Values

[masterlongevity]

Just to be clear, everyone i know, including myself, thinks tysabri is the best tx for MS andis underutilized. But I do think it is almost always good for pts to have more options.

I think at least one of these 2 orals will make it to market. BTW, any idea when tysabri subQ is expected? I feel like they have been talking about it for years.

I also thought Tysabri fared pretty well in the AAN press

[DewDiligence]

…FTY720 [is] very unlikely to get to market, IMO.

You may want to revisit that opinion in light of the votes at today’s advisory panel. Regards, Dew